CSF1R and tenosynovial giant cell tumor: CSF1R-targeting agents are generally well-tolerated in the clinic, and the multi-TKI CSF1R inhibitor Pexidartinib is FDA-approved to treat tenosynovial giant-cell tumor (114, 115).